Interpace Biosciences (IDXG)
(Delayed Data from OTC)
$1.68 USD
+0.05 (3.38%)
Updated Sep 20, 2024 02:41 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Interpace Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 40 | 32 | 41 | 32 | 24 |
Cost Of Goods | 16 | 14 | 23 | 22 | 16 |
Gross Profit | 24 | 18 | 18 | 11 | 8 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 22 | 32 | 37 | 35 |
Income After Depreciation & Amortization | 3 | -4 | -14 | -26 | -26 |
Non-Operating Income | -2 | -2 | -1 | 0 | 0 |
Interest Expense | 0 | 0 | 1 | 1 | 0 |
Pretax Income | 1 | -6 | -15 | -26 | -27 |
Income Taxes | 0 | 0 | -1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1 | -6 | -15 | -26 | -27 |
Extras & Discontinued Operations | 0 | -16 | 0 | 0 | 0 |
Net Income (GAAP) | 1 | -22 | -15 | -26 | -27 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 4 | 7 | -8 | -21 | -22 |
Depreciation & Amortization (Cash Flow) | 2 | 11 | 6 | 6 | 4 |
Income After Depreciation & Amortization | 3 | -4 | -14 | -26 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.36 | 4.24 | NA | 4.03 | 3.75 |
Diluted EPS Before Non-Recurring Items | 0.25 | -1.38 | NA | -7.26 | -5.58 |
Diluted Net EPS (GAAP) | 0.18 | -5.18 | -3.61 | -7.32 | -7.25 |
Fiscal Year end for Interpace Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 12.04 | 10.27 | 10.28 | 9.08 | 11.03 |
Cost Of Goods | 4.61 | 4.20 | 4.15 | 4.12 | 4.19 |
Gross Profit | 7.43 | 6.07 | 6.14 | 4.95 | 6.84 |
SG&A, R&D, and Dept/Amort Expenses | 5.18 | 5.20 | 4.82 | 4.97 | 6.01 |
Income After SG&A, R&D, and Dept/Amort Expenses | 2.25 | 0.87 | 1.32 | -0.02 | 0.83 |
Non-Operating Income | -0.12 | -0.28 | -0.38 | -0.51 | -0.43 |
Interest Expense | 0.00 | 0.02 | 0.11 | 0.00 | 0.00 |
Pretax Income | 2.14 | 0.58 | 0.82 | -0.52 | 0.40 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 2.14 | 0.57 | 0.82 | -0.53 | 0.40 |
Extras & Discontinued Operations | -0.07 | -0.10 | 0.08 | -0.09 | -0.22 |
Net Income (GAAP) | 2.06 | 0.47 | 0.89 | -0.61 | 0.18 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 4.40 | 4.38 | NA | 4.32 | 4.31 |
Diluted EPS Before Non-Recurring Items | 0.48 | 0.13 | NA | -0.12 | 0.09 |
Diluted Net EPS (GAAP) | 0.47 | 0.11 | 0.20 | -0.14 | 0.04 |